bruce_ponder

Cancer Research UK appoints Professor Sir Bruce Ponder as trustee

pharmafile | January 25, 2016 | Appointment | Research and Development Cancer Research UK, Professor Sir Bruce Ponder 

Cancer Research UK has appointed Professor Sir Bruce Ponder as a trustee.

Ponder is emeritus professor of oncology at Cambridge University. He was formerly Li Ka Shing professor of oncology, and founding director of the Cancer Research UK Cambridge Research Institute and of the Cambridge Cancer Centre. He was also co-director of both the Hutchison/MRC Research Centre and the Strangeways Research Laboratories for genetic epidemiology.

Sir Bruce trained in medicine in London and completed a PhD at the Imperial Cancer Research Fund – now known as the Cancer Research UK London Research Institute. He studied medical oncology at the Dana Farber Cancer Institute at Harvard University.

He was an early researcher in the genetics of susceptibility to cancer, establishing clinics to help families with a strong history of cancer, and identifying a gene for one type of familial thyroid cancer. With others, he set up the International Consortium that was behind the discovery of the BRCA1 and BRCA2 breast cancer genes and was its first chair. In 2007 his research group published the first cancer genome-wide association study in breast cancer.

Advertisement

Cancer Research UK chairman Michael Pragnell says: “I’m very pleased to welcome Sir Bruce to our governing Council. He is an internationally renowned cancer researcher and his extensive knowledge and experience will be hugely valuable to the Charity. I much look forward to working with him.”

Related Content

Bowel cancer screening image

Scientists discover reason for resistance to bowel cancer treatment

Scientists funded by Cancer Research UK have demonstrated what may cause some treatments to stop …

towfiqu-barbhuiya-ssz6x-gao0c-unsplash

Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial

Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed …

Cancer Research UK joins forces with Teon to develop new cancer drug

Cancer Research UK and Teon Therapeutics have entered a collaboration agreement to progress the early phase clinical development …

The Gateway to Local Adoption Series

Latest content